I. Executive Summary

This report provides a comprehensive analysis of Bonesupport Holding AB, a commercial-stage orthobiologics company positioned at a significant growth inflection point. The company’s proprietary CERAMENT technology platform, particularly its unique antibiotic-eluting capabilities, serves as the core value driver, enabling it to disrupt established treatment protocols in orthopedic trauma and infection management.

Bonesupport has successfully executed a high-stakes commercial strategy in the United States, culminating in a series of pivotal regulatory approvals and reimbursement wins from 2022 to 2025. These milestones have de-risked its market access and catalyzed a dramatic acceleration in revenue growth, establishing the company as a formidable niche competitor in the bone graft substitutes market. Its technology directly addresses major clinical needs and aligns with powerful secular trends in orthopedics, including the shift toward synthetic grafts, the demand for minimally invasive surgical solutions, and the economic imperative for single-stage procedures.

The company’s financial profile has transformed, marked by an exponential increase in top-line growth driven by the North American market. This rapid scaling has revealed a highly profitable business model, evidenced by consistently high gross margins exceeding 90% and the recent achievement of sustained operating profitability and positive cash flow. This financial inflection suggests the company is now capable of self-funding its ambitious growth plans.

Key future catalysts and opportunities are clearly defined. The primary growth vectors include continued market share gains in the U.S. extremities market, a significant new market entry into the U.S. spinal fusion segment planned for late 2025, and the potential U.S. approval and launch of its second antibiotic-eluting product, CERAMENT V.

Despite the strong momentum, the company faces principal risks inherent to a high-growth medical device firm. These include navigating the regulatory pathway for new products and indications, defending its position against large, entrenched orthopedic competitors, managing the operational complexities of scaling its commercial infrastructure, and executing a seamless leadership transition with an upcoming change in the Chief Executive Officer role.

In conclusion, Bonesupport Holding AB represents a compelling case of a high-growth medical technology company. Its long-term value creation potential is intrinsically linked to its ability to continue its successful U.S. commercial execution, defend its technological leadership in antibiotic-eluting bone grafts, and successfully penetrate the larger, more competitive spinal fusion market.

II. Company Overview & Business Model

Corporate Background

Bonesupport Holding AB is a Swedish-domiciled orthobiologics company, founded in 1999 and publicly listed on the Nasdaq Stockholm exchange under the ticker BONEX.ST.¹ Headquartered in the medical technology hub of Lund, Sweden, the company has established a significant international footprint with a U.S. corporate office in Boston, Massachusetts, and direct sales operations in key European markets, including Germany, the United Kingdom, Switzerland, and the Netherlands.⁴ While its origins are in European med-tech innovation, the company’s strategic focus, operational resources, and recent financial performance are now overwhelmingly centered on the North American market.

The CERAMENT Technology Platform

The foundation of Bonesupport’s business is its patented and proprietary CERAMENT technology platform. This platform produces an injectable, bio-ceramic bone graft substitute designed to fill bone voids and facilitate the body’s natural healing process.¹ The material’s core innovation lies in its unique biphasic composition: a mixture of 60% calcium sulfate (

CaSO4​) and 40% hydroxyapatite (Ca10​(PO4​)6​(OH)2​).⁶

This formulation is engineered for controlled, sequential resorption. Upon injection into a bone defect, the fast-resorbing calcium sulfate component begins to dissolve, creating space and a calcium-rich environment that encourages the infiltration of host cells and blood vessels. This leaves behind the slower-resorbing hydroxyapatite particles, which act as an osteoconductive scaffold—a framework upon which new bone can form. This process is designed to synchronize the rate of material resorption with the rate of new bone formation, leading to the complete remodeling of the graft into the patient’s own host bone, a process that typically occurs within a 6 to 12-month timeframe.⁷

This dual-material composition represents a significant technical differentiation from other synthetic grafts. Pure calcium sulfate products can resorb too quickly, before bone has fully formed, while grafts based solely on hydroxyapatite or other calcium phosphates can persist in the body for years, potentially impeding complete remodeling. The CERAMENT platform’s objective is to achieve an ideal balance, providing initial stability and then gradually giving way to natural bone.

Primary Product Portfolio

Bonesupport has commercialized a focused portfolio of products based on the CERAMENT platform, creating a tiered offering that addresses progressively complex clinical needs.

• CERAMENT® Bone Void Filler (BVF): This is the foundational product of the platform. It is an injectable, radiopaque, and osteoconductive synthetic bone void filler used in a wide range of orthopedic and trauma procedures to fill defects caused by injury, disease, or surgery.⁶ It is positioned as a synthetic alternative to autograft (bone harvested from the patient’s own body), which has long been the clinical “gold standard” but requires a second surgical site with associated risks of pain, infection, and increased blood loss.¹⁰
• CERAMENT® G (Gentamicin): This is a first-in-class, drug-eluting variant that combines the CERAMENT BVF scaffold with the broad-spectrum antibiotic gentamicin.⁶ Its defining feature is the ability to elute the antibiotic locally at the surgical site, providing a high concentration of drug to protect the healing bone from bacterial colonization and infection.¹¹ This dual-action capability—simultaneously promoting bone healing and preventing infection—enables surgeons to manage complex conditions like chronic osteomyelitis (bone infection) in a single surgical procedure, a paradigm shift from traditional multi-stage treatments.¹²
• CERAMENT® V (Vancomycin): This is a second drug-eluting product that incorporates the antibiotic vancomycin into the CERAMENT scaffold.⁶ Vancomycin targets a different spectrum of bacteria than gentamicin, particularly gram-positive organisms such as Methicillin-resistant
  Staphylococcus aureus (MRSA), providing surgeons with another critical tool for infection management. This product is commercially available in Europe but is not yet approved for sale in the United States.¹⁵

The portfolio structure allows Bonesupport to compete across different segments of the bone graft market. While BVF addresses the broader bone void filler space, the antibiotic-eluting products, CERAMENT G and CERAMENT V, target a more complex, high-value clinical challenge where there are few, if any, direct competitors offering a resorbable, single-stage solution. This creates a significant competitive moat and is the primary driver of the company’s recent commercial success.

Revenue Model and Geographic Distribution

Bonesupport generates revenue almost exclusively from the sale of its CERAMENT products through a hybrid commercial model tailored to different markets.

• North America: In the U.S., the company’s largest and fastest-growing market, it employs a dual approach combining its own direct commercial organization with a network of independent sales distributors.¹⁶ This structure allows for broad geographic coverage while maintaining direct relationships with key opinion leaders and hospital systems.
• Europe: In key European markets, including the United Kingdom, Germany, Sweden, Denmark, and the Netherlands, Bonesupport utilizes a direct sales force of its own employees.³
• Rest of World: In other markets, including parts of Europe (e.g., Spain, Italy), SE Asia, and the Middle East, the company relies on a network of third-party distributors.³

The company’s geographic revenue mix has undergone a profound transformation. In 2023, the North America segment generated SEK 442 million, accounting for approximately 75% of total company sales, while the EU & Rest of World (EUROW) segment contributed SEK 149 million, or 25%.¹⁶ This is a direct consequence of a pivotal strategic decision in 2018 to terminate an exclusive U.S. distribution agreement with Zimmer Biomet and invest in building a dedicated American commercial platform.¹⁷ This move, while disruptive in the short term, has proven immensely successful and has made the company’s performance overwhelmingly dependent on its execution in the U.S. market.

Regulatory Pathway and Status

Bonesupport’s products are subject to rigorous regulatory oversight in all markets where they are sold.

• Europe: The CERAMENT portfolio carries the CE mark and is classified as a Class III medical device, the highest risk class. As of December 2023, the company’s entire product line is fully compliant with the European Union’s new, more stringent Medical Device Regulation (MDR) 2017/745, a significant regulatory accomplishment that not all competitors have achieved.¹⁶
• United States: The company has navigated a series of critical and successful regulatory pathways with the U.S. Food and Drug Administration (FDA).

• CERAMENT G (Bone Infection): In a landmark event for the company, CERAMENT G received market authorization for the indication of bone infection (osteomyelitis) in May 2022.²² This was granted through the
  De Novo classification process, a specific pathway for novel, low-to-moderate risk medical devices that have no legally marketed predicate device.²² The FDA also granted the product a
  “Breakthrough Device” designation, which provides for a more collaborative and prioritized review process.²² The successful navigation of the De Novo pathway was a pivotal, company-defining event. A standard 510(k) clearance requires a company to demonstrate “substantial equivalence” to an existing device. Because no such device existed for CERAMENT G, the De Novo process was necessary. In succeeding, Bonesupport not only validated its product’s novelty but also worked with the FDA to establish an entirely new device classification (under 21 CFR 888.3046) for a “resorbable calcium salt bone void filler containing a single approved aminoglycoside antibacterial”.²³ This action effectively raised the regulatory bar for any future competitor wishing to enter this specific market segment, as they must now meet the standards and special controls established by Bonesupport’s submission, creating a durable competitive advantage.
• CERAMENT G (Open Fractures): In March 2024, the company received an expanded 510(k) clearance for CERAMENT G for use in open fractures, a trauma indication with a high risk of infection. This clearance more than doubled the product’s addressable market in the U.S..¹⁶
• CERAMENT V: The company plans to submit a market application for CERAMENT V in the U.S. during the first quarter of 2025. Following discussions with the FDA, this will proceed via the 510(k) pathway, using the now-established CERAMENT G as the predicate device.²⁶
• Asia-Pacific: The company has a commercial presence in Southeast Asia via distributors and has formally initiated the regulatory process to gain market access in Japan, one of the world’s largest orthopedic markets.²⁰

III. Industry Dynamics & Market Analysis

Global Orthobiologics Market Size and Growth

Bonesupport operates within the global orthobiologics market, a large and steadily growing segment of the broader orthopedics industry. Market size estimates for 2023-2024 range from approximately USD 6.8 billion to USD 9.2 billion.²⁹ Projections indicate the market will expand at a compound annual growth rate (CAGR) of approximately 5-6%, reaching a value between USD 11 billion and USD 14 billion by 2032-2034.²⁹

The bone graft substitutes market, a key sub-segment, was valued at approximately USD 3-4 billion in 2023-2024 and is forecast to grow at a similar CAGR of 5-6.5%.³⁶ Geographically, North America is the most significant market, accounting for nearly 50% of global orthobiologics sales, driven by high procedure volumes, rapid adoption of new technologies, and a well-established reimbursement infrastructure.²⁹

Key Market Drivers and Trends

Several powerful, long-term secular trends underpin the growth of the orthobiologics market and are particularly favorable to Bonesupport’s product portfolio.

• Aging Demographics: The global population is aging, with the number of individuals aged 65 and over expected to reach 1.6 billion by 2050.³⁰ This demographic shift is a primary driver of market growth, as older populations have a higher incidence of degenerative bone diseases such as osteoarthritis and osteoporosis, which frequently require surgical intervention and the use of bone graft materials.³⁰
• Increasing Trauma Cases and Sports Injuries: High volumes of orthopedic trauma resulting from road accidents and an increase in sports-related injuries among an active population contribute significantly to the demand for effective bone repair products.³⁰ Open fractures, a key indication for CERAMENT G, are a common outcome of severe trauma.
• Shift from Traditional Grafts to Synthetic Substitutes: The market is experiencing a clear and accelerating trend away from traditional bone grafting materials.

• Autograft, harvested from the patient’s own iliac crest, has long been considered the “gold standard” due to its inherent osteoconductive, osteoinductive, and osteogenic properties. However, it necessitates a second surgical site, which is associated with significant drawbacks, including chronic donor site pain, increased blood loss, longer operating times, and risk of infection.¹⁰
• Allograft, derived from human cadaveric donors, eliminates donor site morbidity but introduces risks of disease transmission and immunogenic reactions, and its biological properties can be highly variable.⁴³
• As a result, there is a strong clinical and patient preference for high-quality synthetic substitutes that offer safety, consistency, and off-the-shelf availability without the drawbacks of autograft or allograft. The synthetic segment is widely projected to be the fastest-growing category within the bone grafts market.²⁹
• Preference for Minimally Invasive Surgery (MIS): A dominant trend across all surgical disciplines is the move toward minimally invasive procedures. MIS offers patients benefits such as smaller incisions, less pain, reduced risk of infection, and faster recovery times.⁴² This trend directly fuels demand for biomaterials that are compatible with these techniques. Injectable and flowable bone graft substitutes, like the CERAMENT paste, are ideally suited for delivery through cannulas in MIS procedures, whereas traditional block-style grafts are not.³²

Bonesupport’s CERAMENT platform is uniquely positioned at the confluence of these powerful market forces. It is a synthetic product, addressing the shift away from autograft and allograft; it is injectable, making it ideal for minimally invasive surgery; and its antibiotic-eluting variants provide a novel solution for the complex challenges of trauma and infection that are driven by underlying demographic and lifestyle trends. This positioning allows the company to benefit not just from overall market growth, but from capturing share from older, less favorable technologies.

Competitive Landscape

The orthobiologics market is competitive and includes some of the largest and most established companies in the medical device industry. The landscape is dominated by diversified orthopedic giants such as:

• Medtronic plc ⁴⁷
• Stryker Corporation ⁴⁷
• Zimmer Biomet Holdings, Inc. ⁴⁷
• DePuy Synthes (a Johnson & Johnson company) ⁴⁷

These incumbents possess immense scale, global distribution networks, extensive product portfolios, and deeply entrenched relationships with hospitals and Group Purchasing Organizations (GPOs). They compete with a wide range of orthobiologic products, including allografts, demineralized bone matrix (DBM), and their own synthetic substitutes, such as Medtronic’s well-known INFUSE Bone Graft (a bone morphogenetic protein), Stryker’s Vitoss (a beta-tricalcium phosphate), and Zimmer Biomet’s Triosite and genex products.⁵⁰ Bonesupport operates as a specialized, pure-play competitor, focusing its strategy on leveraging a distinct technological advantage in a specific clinical niche rather than competing across the entire orthopedic spectrum.

Barriers to Entry

The orthobiologics market is characterized by substantial barriers to entry, which protect established players but make it difficult for new companies to emerge.

• Regulatory Hurdles: Gaining market approval for new medical devices is a lengthy, complex, and expensive process. Pathways such as the Premarket Approval (PMA) or De Novo classification in the U.S. can require investments of tens to hundreds of millions of dollars and take many years to complete, involving extensive preclinical and clinical trials.⁵⁴
• Clinical Evidence Requirements: Surgeon adoption is driven by robust clinical data. Generating high-level evidence, such as Level 1 randomized controlled trials, is a significant investment in time and capital but is essential for changing clinical practice and gaining inclusion in treatment guidelines.⁵⁴
• Distribution and Market Access: New entrants face the challenge of building a commercial infrastructure and gaining access to hospital contracts. Large incumbents leverage their broad product portfolios and long-standing relationships to secure exclusive or favorable contracts with hospital systems and GPOs, making it difficult for smaller companies with niche products to get on the shelf.⁵⁴

Bonesupport has already successfully navigated these formidable barriers, particularly in the crucial U.S. market. Its regulatory approvals, extensive clinical data package, and established distribution network now function as a competitive moat against potential new entrants in the antibiotic-eluting bone graft segment.

Pricing and Reimbursement Environment

The adoption of any new medical technology is critically dependent on the reimbursement landscape. In the U.S., securing adequate payment from the Centers for Medicare & Medicaid Services (CMS) and private payers is paramount. Bonesupport has achieved several key reimbursement milestones for CERAMENT G that have been instrumental in its commercial success. The company has secured a New Technology Add-On Payment (NTAP) for inpatient procedures and a Transitional Pass-Through (TPT) payment for outpatient procedures.⁵ These programs provide hospitals with additional reimbursement on top of the standard diagnosis-related group (DRG) payment for a procedure. This is crucial because it mitigates the financial risk for hospitals in adopting a new, premium-priced technology, effectively removing a major barrier to adoption and accelerating market penetration. Most recently, in August 2025, CMS approved an NTAP for CERAMENT G in open fractures, providing up to an additional $5,687.50 per case.⁵

IV. Competitive Position & Differentiation

Unique Value Proposition

Bonesupport’s core competitive advantage and primary value proposition stem from its unique ability to offer a fully resorbable, antibiotic-eluting bone graft that facilitates a single-stage surgical procedure for complex bone voids, particularly those complicated by infection.¹² This stands in stark contrast to the traditional standard of care for conditions like chronic osteomyelitis.

The conventional approach often involves a multi-stage treatment protocol. First, the surgeon performs a debridement to remove infected and necrotic bone. The resulting dead space is then filled with a temporary, non-resorbable antibiotic spacer, most commonly polymethylmethacrylate (PMMA) beads impregnated with an antibiotic. The patient then undergoes a weeks-long course of systemic antibiotic therapy. Finally, a second major surgery is required to remove the PMMA spacer and implant a bone graft to reconstruct the defect.⁵⁷

CERAMENT G disrupts this paradigm. Its dual-action capability allows the surgeon to debride the infected bone and fill the resulting void with a single material that both elutes antibiotics locally to manage the infection and provides a scaffold for new bone growth. Because CERAMENT G is fully resorbable, no second surgery is needed for removal. This single-stage approach provides a powerful health-economic argument, offering the potential to reduce the total number of surgeries, lower the risk of complications associated with multiple procedures, shorten hospital stays, and ultimately decrease the total cost of care.⁵⁸ For healthcare systems increasingly focused on value-based care and operating under fixed-reimbursement models, this is a highly compelling proposition.

Clinical Evidence vs. Competitors

Bonesupport has strategically invested in building a robust body of clinical evidence to validate its technology and drive surgeon adoption, with over 350 publications and abstracts supporting the CERAMENT platform.⁶ This evidence base is a key competitive tool, particularly when compared to the traditional standard of care.

Attribute	CERAMENT G	Standard of Care (PMMA Beads)
Resorbability	Fully resorbable; remodels to host bone in 6-12 months.13	Non-resorbable; requires a second surgery for removal.57
Surgical Protocol	Enables a single-stage procedure for debridement and reconstruction.12	Requires a multi-stage procedure with spacer implantation and later removal.57
Antibiotic Elution	High initial “burst” release followed by a sustained release above MIC for at least 28 days. All antibiotic is released as the material resorbs.11	Relies on surface diffusion. High initial release for 48-72 hours, then falls to lower, sub-therapeutic levels. Incomplete release of antibiotic.57
Clinical Outcome	High infection eradication rates (90-96%) and limb salvage rates in complex cases like chronic osteomyelitis and diabetic foot infection.11	Effective, but associated with the morbidity and cost of multiple surgeries.
Health Economic	A U.S. health economic model estimated average cost savings of USD 27,943 per patient compared to PMMA beads due to fewer surgeries and complications.58	Higher total cost of care due to multiple hospital admissions and surgical procedures.

Table 2: CERAMENT G vs. Standard of Care (PMMA Beads). This table summarizes the key differentiators based on clinical and health economic data.

Furthermore, the foundational CERAMENT BVF product has been validated in a Level 1 randomized controlled trial (RCT), the highest level of clinical evidence. The CERTiFy study, published in the Journal of Bone and Joint Surgery, demonstrated that CERAMENT BVF is non-inferior to autograft for bone remodeling in tibial plateau fractures, but resulted in significantly less post-operative pain and blood loss for the patient.¹⁰

While large competitors like Medtronic and Stryker have their own extensive clinical data packages for their flagship products, such as Medtronic’s INFUSE for spinal fusion or Stryker’s Augment for ankle and hindfoot fusion, Bonesupport’s evidence is uniquely focused and powerful within its specific niche of resorbable, antibiotic-eluting grafts for infection management.⁶² This targeted, evidence-based approach allows a smaller company to effectively challenge a decades-old standard of care and win business from much larger, less-focused competitors.

Intellectual Property Portfolio

Bonesupport’s technology is protected by a comprehensive intellectual property portfolio, which includes approximately 100 registered and/or pending patents.⁶⁴ This portfolio creates a layered defense against potential competitors by covering not only the novel material composition of CERAMENT but also key components of the delivery system, such as the combined mixing-injection syringe that ensures proper preparation and handling.⁶⁶

A review of granted U.S. patents indicates protection for the core technology, specifically related to hardenable bone substitute compositions comprising calcium sulfate and heat-treated hydroxyapatite to achieve improved setting properties.⁶⁷ For example, U.S. Patent No. 10,994,998, granted in May 2021, provides protection that extends into the 2030s, securing the company’s proprietary technology for a significant period. The combination of patents on the material itself and the associated delivery devices creates a formidable barrier to entry for companies seeking to develop a directly competing product.

Distribution Network and Surgeon Relationships

A critical component of Bonesupport’s recent success has been the strategic overhaul of its U.S. commercial channel. In May 2018, the company terminated its exclusive distribution agreement with Zimmer Biomet, a move that temporarily depressed sales but gave it direct control over its destiny in its most important market.¹⁷

Since then, the company has built a robust U.S. commercial platform consisting of its own sales management team and a network of independent distributors. At the time of the transition, this network comprised 25 distributors employing over 500 sales representatives.¹⁸ The company’s selection criteria for these distributors prioritize those with strong, pre-existing relationships with orthopedic surgeons in key specialties like trauma, total joint arthroplasty, and foot & ankle surgery.¹⁸ The success of this transition is now clearly reflected in the company’s explosive U.S. sales growth.

In a further strategic move to access a niche market, Bonesupport entered into a distribution agreement with OrthoPediatrics in 2022. This partnership leverages OrthoPediatrics’ specialized sales force to promote CERAMENT BVF in over 250 children’s hospitals across the U.S., a segment that Bonesupport would have found difficult and costly to penetrate on its own.⁶⁸ This demonstrates a capital-efficient approach to market expansion.

Market Share Trends

While Bonesupport remains a small player in the overall global orthopedics market, it is achieving rapid and significant market share gains within its targeted niches. According to an equity research report from ABG Sundal Collier, Bonesupport’s U.S. market share for CERAMENT G in the extremities market is forecast to grow from an estimated 5.6% in 2024 to 8.6% in 2025, 11.3% in 2026, and 14.7% in 2027.⁶⁹ In its mature European direct markets, the company has already captured an estimated 8% share of the local antibiotics segment.²⁸ This demonstrates a clear pattern of successful market penetration and share capture from incumbent technologies and competitors.

V. Financial Performance & Growth Analysis

Revenue Growth Trajectory (2018-2024)

Bonesupport’s financial performance over the past seven years illustrates a classic “hockey stick” growth curve, marking a clear transition from a development-stage company to a high-growth commercial entity. The period from 2018 to 2021 represented a phase of strategic repositioning and investment, particularly in the U.S. market, followed by a dramatic acceleration in growth from 2022 onwards.

Net sales grew from SEK 96.6 million in 2018 to SEK 898.7 million in 2024, representing a compound annual growth rate of 45% over the six-year period.³ The growth has been even more pronounced in recent years. Following the pivotal U.S. FDA approval of CERAMENT G in May 2022, the company’s growth trajectory inflected sharply, with total revenue growing 54.5% in 2022, 79.8% in 2023, and 52.0% in 2024.³

This explosive growth has been almost entirely driven by the North America segment. U.S. sales grew by 104% in 2023 and 62% in 2024 (63% in constant currency).³ In contrast, the more mature Europe & Rest of World (EUROW) segment grew by a solid but more modest 33% and 23% in the same years.³ This has fundamentally shifted the company’s revenue profile, with North America now accounting for the vast majority of total sales.

An analysis of sales by product line further confirms that the antibiotic-eluting products are the primary growth engine. In 2023, sales of CERAMENT G and CERAMENT V grew by 219% to SEK 358.2 million, while sales of the base CERAMENT BVF product grew by a much slower 6% to SEK 223.1 million.¹⁶

Gross Margins and Operating Leverage

A key feature of Bonesupport’s financial profile is its exceptionally high and stable gross margin, which is indicative of a proprietary, high-value product with significant pricing power. Gross margins have consistently improved, rising from 84% in 2018 to 89% in 2020, and reaching 92.6% for the full year 2024.³

The rapid revenue scaling combined with this high gross margin has unlocked powerful operating leverage. After years of operating losses while investing in R&D and commercial infrastructure, the company reached a critical inflection point in 2023, reporting its first full-year operating profit of SEK 13.9 million. This represented a dramatic turnaround from the SEK -64.5 million operating loss recorded in 2022.¹⁶ The momentum continued and strengthened significantly in 2024, with the company reporting a full-year operating profit of SEK 166.1 million.³ This rapid swing to profitability demonstrates a highly scalable business model where revenues are now growing at a much faster rate than operating expenses.

Metric (SEK, millions)	2020	2021	2022	2023	2024
Net Sales (Total)	180.9	212.9	328.8	591.1	898.7
YoY Growth %	16.3%	17.7%	54.5%	79.8%	52.0%
Net Sales (North America)	67.3	91.1	216.9	442.4	721.4
YoY Growth % (NA)	47.0%	35.4%	138.1%	104.0%	63.1%
Net Sales (EUROW)	113.6	121.8	111.9	148.6	177.3
YoY Growth % (EUROW)	-7.0%	7.2%	-8.1%	32.8%	19.3%
Gross Profit	161.7	189.7	297.6	541.0	832.3
Gross Margin %	89.4%	89.1%	90.5%	91.5%	92.6%
Operating Income/(Loss)	(98.6)	(80.7)	(64.5)	13.9	166.1
Operating Margin %	-54.5%	-37.9%	-19.6%	2.4%	18.5%
Operating Cash Flow	(100.3)	(83.4)	(47.0)	(18.3)	N/A

Table 1: Five-Year Financial Summary (2020-2024). Data compiled from company annual and year-end reports. Note: Geographic sales for 2020-2022 are derived from segment data in various reports and may have slight rounding differences. 2024 geographic sales are estimated based on reported growth rates. ³

Working Capital and Cash Flow

The company’s rapid growth has naturally led to an increase in working capital requirements, with capital tied up in trade receivables and inventory expanding in line with sales.¹⁶ Despite this, cash flow from operations has improved dramatically. After years of cash consumption, the company began generating positive operating cash flow in the third and fourth quarters of 2023.¹⁶ This trend continued into 2025, with the company reporting a strong operating cash flow of SEK 50 million in the second quarter alone.⁷² As of the end of Q2 2025, Bonesupport held a solid cash position of SEK 309.7 million.⁷² This indicates that the company is now largely self-funding its growth initiatives through its own operations, significantly reducing the near-term need for external financing.

R&D Investment

As Bonesupport has transitioned from a development-focused to a commercially-driven company, its R&D spending as a percentage of revenue has naturally declined. In absolute terms, R&D expenses have remained relatively stable, totaling SEK 53.1 million in 2022 and SEK 57.1 million in 2023.¹⁶ However, due to the rapid increase in the revenue base, R&D as a percentage of sales fell from 16.2% in 2022 to just 9.7% in 2023.¹⁶ This reflects the company’s shift in focus from foundational research to commercial execution and clinical studies designed to support market expansion for existing products.

Capital Raising and Dilution

Bonesupport has executed two major capital-raising events since its inception. The first was its Initial Public Offering (IPO) on the Nasdaq Stockholm exchange in June 2017.⁶⁴ The second was a critical directed share issue in May 2020, which raised approximately SEK 378 million. These funds were explicitly earmarked to finance the build-out of the U.S. commercial organization and fund the clinical trials necessary to secure FDA approval for CERAMENT G.¹⁹ While this was a dilutive event for existing shareholders, it was a necessary and timely strategic move that provided the capital required to unlock the subsequent phase of explosive growth. The total number of shares outstanding has increased from approximately 48.8 million post-IPO (assuming full over-allotment) to 66.8 million at the end of 2024.³

VI. Recent Developments & Challenges (2023-2025)

The period from 2023 through mid-2025 has been transformational for Bonesupport, characterized by a series of significant regulatory approvals, positive clinical data readouts, and strategic announcements that have fundamentally de-risked the business and accelerated its growth trajectory.

Significant Regulatory and Reimbursement Approvals

The company has achieved a string of crucial successes with U.S. regulatory and reimbursement bodies, systematically unlocking the commercial potential of the CERAMENT platform.

Date	Agency	Event	Significance/Impact on Addressable Market
Oct 2023	FDA	CERAMENT V awarded “Breakthrough Device” designation for bone infection.27	Signals regulatory recognition of the product’s potential and provides a prioritized review pathway for its future submission.
Nov 2023	CMS	Transitional Pass-Through (TPT) payment granted for CERAMENT G.27	Provides additional reimbursement for use in the outpatient setting, removing a key financial barrier to adoption in ambulatory surgery centers.
Mar 2024	FDA	CERAMENT G receives 510(k) clearance for use in open fractures.24	More than doubles the addressable market for CERAMENT G in the U.S. by expanding its indication into the large trauma segment.
Mar 2024	FDA	CERAMENT BVF receives 510(k) clearance for spinal interbody fusion procedures.25	Provides the regulatory foundation for the company’s planned strategic entry into the U.S. spinal fusion market.
Mar 2025	FDA	Market authorization application (510(k)) submitted for CERAMENT V for bone infection.75	Initiates the regulatory process for the company’s second antibiotic-eluting product in the U.S.
Aug 2025	CMS	New Technology Add-On Payment (NTAP) approved for CERAMENT G in open fractures.5	Provides up to ~$5,688 in additional reimbursement for inpatient hospital use, strongly incentivizing adoption in the new trauma indication.

Table 3: Key Regulatory & Reimbursement Milestones (U.S. Market). This table highlights the sequence of successful regulatory and reimbursement events that have enabled Bonesupport’s U.S. commercial ramp.

Clinical Trial Results and Publications

Bonesupport has continued to bolster its clinical evidence base with important new data.

• SOLARIO Study (September 2024): Topline results from the SOLARIO study were presented, which investigated the necessary duration of systemic antibiotic therapy when used in conjunction with a local antibiotic-eluting bone substitute like CERAMENT G or V. The results showed that patients achieved equally good infection prevention with a shorter course of systemic antibiotics, suggesting a potential to change treatment standards, reduce the risk of antibiotic resistance, and lower healthcare costs.⁷⁶
• Diabetic Foot Infection Study (January 2025): A clinical study involving 105 diabetes patients with bone infection in the foot was reported. The results showed that surgical treatment including CERAMENT G or CERAMENT V led to a dramatic improvement in the five-year survival rate to 87.5%, compared to just 44.9% in the standard treatment group.⁷⁴ This powerful data highlights the product’s ability to improve outcomes in a very high-risk and costly patient population.

Management Changes

The company is navigating a significant leadership transition. In March 2024, Kristina Ingvar, the Executive Vice President of Quality Management & Regulatory Affairs, departed the company to take a position at Novo Nordisk.⁷⁷ More consequentially, in April 2025, the company announced that Emil Billbäck, who has served as CEO since 2018 and has overseen the company’s strategic transformation and successful U.S. launch, will transition to a role as Senior Advisor. Torbjörn Sköld, an executive with extensive experience in the MedTech and orthopedics sectors, will assume the role of CEO, effective September 1, 2025.⁵⁵ In a sign of confidence, the incoming CEO acquired approximately SEK 3.8 million worth of BONESUPPORT shares in June 2025.⁸⁰ While the transition appears well-managed, with the outgoing CEO remaining in an advisory capacity, any change in leadership during a period of such rapid growth introduces an element of execution risk.

Challenges

• Healthcare Procedure Volumes: While surgical procedure volumes in the U.S. have largely recovered to pre-pandemic levels, the recovery in some European markets has been slower, primarily due to persistent hospital staffing shortages.⁸¹ This has acted as a headwind to growth in the EUROW segment.
• Competitive Threats: The orthobiologics market remains highly competitive. Established players are continually launching new synthetic bone graft products, such as Orthofix’s OsteoCove and Anika Therapeutics’ Tactoset, which compete for surgeon attention and hospital contracts, even if they do not offer the same antibiotic-eluting feature.²⁹
• Macroeconomic Factors: As a Swedish company reporting in SEK with the majority of its revenue generated in USD, Bonesupport is exposed to foreign exchange risk. A strengthening of the krona against the dollar can create a translational headwind, negatively impacting reported revenue and profit figures, as was the case in the first quarter of 2025.⁷⁵ The company has also previously highlighted the potential negative financial impact of any future U.S. import tariffs on European goods.²¹

VII. Growth Strategy & Opportunities

Geographic Expansion Strategy

Bonesupport’s growth strategy is sharply focused on capitalizing on its recent regulatory and commercial successes, with a clear prioritization of markets and applications.

• Deepen U.S. Market Penetration in Extremities: The foremost strategic priority is to continue driving the adoption of CERAMENT G in the U.S. extremities market. This involves leveraging the dual indications for both bone infection and, more recently, the prevention of infection in open fractures.¹⁹ The strategy relies on expanding the user base of surgeons, increasing the utilization per surgeon, and securing listings with additional hospital systems and GPOs.
• Launch into the U.S. Spine Market: The most significant new growth vector for the company is its planned entry into the U.S. spinal fusion market. The company received FDA 510(k) clearance for CERAMENT BVF in interbody fusion procedures in March 2024 and is planning a commercial launch in December 2025.²⁷ The spinal fusion market is the single largest application for bone graft substitutes, representing nearly half of the total market and an estimated 750,000 annual procedures in the U.S..¹⁶ Successfully capturing even a small fraction of this market would have a material impact on Bonesupport’s overall revenue. However, this initiative also carries significant execution risk, as it will pit the company against highly entrenched competitors, most notably Medtronic and its dominant INFUSE (BMP-2) product. Bonesupport’s strategy involves recruiting a dedicated network of independent spine distributors and initiating clinical data generation within 12 months of launch to support adoption.⁸²
• Develop Asian Markets: In the longer term, the company is targeting expansion into major Asian markets. It has identified Japan, a large and sophisticated orthopedic market, as a key target and has initiated the regulatory process to gain market access.²⁸ The company already has a commercial presence in parts of Southeast Asia through local distributors.²⁰

Pipeline Products and Line Extensions

The company’s R&D strategy is focused on leveraging the proven CERAMENT platform to create new, high-value products.

• CERAMENT V (Vancomycin) U.S. Launch: The most immediate pipeline opportunity is the U.S. launch of CERAMENT V. The company submitted its 510(k) application to the FDA in the first quarter of 2025, with a potential launch anticipated in the first half of 2026.²⁷ The availability of a vancomycin-eluting option alongside the gentamicin-eluting CERAMENT G would provide surgeons with a critical tool to manage a broader spectrum of bacterial infections, particularly those caused by resistant gram-positive organisms.
• Next-Generation Combination Products: The company’s preclinical pipeline is exploring new combinations to add osteoinductive properties (the ability to actively stimulate bone formation) to the CERAMENT scaffold. Priority candidates for in-house development include combining CERAMENT with bisphosphonates, which could create a product for treating osteoporotic fractures by simultaneously providing a scaffold and a drug that inhibits bone resorption, and combining CERAMENT with demineralized bone matrix (DBM). The company views a combination with bone morphogenic proteins (BMPs) as a potential candidate for development with a strategic partner.¹⁷ Success in developing a product for osteoporosis could open up a vast new market opportunity.

Strategic Partnerships

Bonesupport has historically used strategic partnerships as a capital-efficient means to broaden its product portfolio and enhance its commercial appeal. In 2018, during the build-out of its U.S. channel, the company signed agreements with MTF Biologics and Collagen Matrix to distribute their DBM and collagen-based products.¹⁷ This allowed Bonesupport to offer its new distributor network a more complete “bag” of bone void solutions, making it a more attractive partner and better able to compete for hospital contracts against full-line orthopedic companies. The company continues to evaluate partnership opportunities for pipeline products, such as a potential BMP combination.⁸⁵

VIII. Capital Allocation & Financial Management

Capital Allocation Priorities

Management’s capital allocation strategy is unequivocally focused on reinvesting capital to drive long-term growth. The proceeds from the company’s 2020 directed share issue were explicitly used to fund the key pillars of its growth strategy: the expansion of the U.S. commercial infrastructure, the generation of pivotal clinical data to support regulatory approvals and drive adoption, and the continued development of the product pipeline.¹⁹ There is no indication that a return of capital to shareholders through dividends or buybacks is a near-term priority. The company’s actions demonstrate a clear belief that the highest return on capital can be achieved by reinvesting in its high-growth commercial opportunities.

Financial Position and Funding Requirements

Bonesupport maintains a strong and conservative financial position. The company’s balance sheet is effectively debt-free, with no bank loans outstanding. Its only interest-bearing liabilities consist of minor leasing obligations, which amounted to just SEK 17.5 million at the end of 2023.¹⁶

The company is well-capitalized to fund its current operational plan. Following the 2020 capital raise and the recent turn to profitability, the company has a solid cash position, which stood at SEK 309.7 million at the end of the second quarter of 2025.⁷² Critically, the business is now generating positive operating cash flow, indicating that it can self-fund its ongoing growth initiatives, including the commercial launch into the U.S. spine market, without the immediate need for additional external financing.

Dividend Policy and Share Repurchase History

Consistent with its status as a high-growth company, Bonesupport has never paid a dividend. The company’s stated policy is that any future dividends will be contingent upon its long-term growth trajectory, earnings development, and capital requirements.³

The company does not have a history of share repurchases for the purpose of capital return. The Board has, on occasion, resolved to repurchase shares, but these actions are specifically to secure the company’s obligations to deliver shares to employees under its long-term, share-based incentive programs.¹⁶

Track Record of Meeting Financial Guidance

Bonesupport’s management has established a credible track record of setting and achieving ambitious financial targets.

• In November 2023, the company provided guidance for full-year 2024 sales growth to be “above 40 percent” in constant currency.²⁷
• Following a strong performance in the first half of the year, this guidance was raised in July 2024 to “over 50 percent”.⁹⁰
• The company ultimately delivered full-year 2024 sales growth of 52% in constant currency, exceeding its upgraded guidance.³

This history of meeting and exceeding publicly stated financial targets enhances management’s credibility with the investment community.

Insider Ownership and Alignment with Shareholder Interests

There is evidence of strong alignment between the interests of Bonesupport’s management team and its shareholders. Members of the Board of Directors and the Group Management team hold significant personal equity stakes in the company.¹⁶ For instance, the outgoing CEO, Emil Billbäck, held over 363,000 shares as of October 2024, and the incoming CEO, Torbjörn Sköld, made a substantial personal investment of approximately SEK 3.8 million upon being named to the position.⁸⁰

Furthermore, the company utilizes long-term incentive (LTI) programs that tie executive and employee compensation directly to performance metrics that drive shareholder value, such as share price appreciation, sales growth, and EBITDA targets.¹⁶ While there have been instances of insider selling, these have been publicly disclosed as being primarily for the purpose of covering personal tax obligations arising from the vesting of these LTI shares, rather than a lack of confidence in the company’s prospects.⁹¹ The combination of significant insider ownership and performance-based compensation structures suggests that management is highly motivated to achieve long-term growth and value creation.

IX. Risk Assessment

Regulatory and Reimbursement Risks

• Regulatory Hurdles: The company’s future growth is partly dependent on securing new regulatory approvals. While Bonesupport is pursuing a 510(k) pathway for CERAMENT V in the U.S., which is generally less burdensome than a PMA or De Novo process, there is no guarantee of a timely approval or that the FDA will not require additional data.²⁶ Any significant delay or rejection of the CERAMENT V application would be a setback to the company’s growth plans and its competitive positioning in infection management. Similarly, future expansion of indications for any product, particularly into spine, will require new regulatory clearances.
• Reimbursement Uncertainty: Bonesupport’s U.S. success has been significantly aided by temporary reimbursement programs like NTAP and TPT, which provide hospitals with additional payments for using its technology.⁵⁶ These programs are, by definition, not permanent. The company’s long-term success depends on its products being incorporated into standard DRG and other payment systems at a level that justifies their premium price. Any future adverse changes in CMS policy or a failure to secure adequate long-term reimbursement could negatively impact hospital adoption and sales volumes.

Clinical and Product Liability Risks

• Product Liability: As a manufacturer of implantable medical devices, Bonesupport is inherently exposed to product liability risk. While the CERAMENT platform has a long track record of safety, any unforeseen adverse events, manufacturing defects, or patient complications could lead to regulatory scrutiny, product recalls, costly litigation, and significant damage to the company’s brand and reputation. An MAUDE adverse event report from the FDA database in February 2025 noted a patient death following a procedure where CERAMENT BVF was used, with the report citing “synthetic bone graft embolization” as a potential cause.⁹⁴ While this appears to be an isolated event and may be attributable to factors such as off-label use or surgical technique, any emergence of a pattern of serious adverse events would represent a major risk.

Competitive and Market Risks

• Intense Competition: The orthobiologics market is dominated by large, well-funded competitors with extensive resources, including Medtronic, Stryker, and Zimmer Biomet.⁴⁷ While these companies currently lack a direct competitor to CERAMENT G, they possess the R&D capabilities to potentially develop their own antibiotic-eluting solutions in the future. Furthermore, they can leverage their broad product portfolios and commercial scale to create product bundles and secure exclusive hospital contracts, which could be used to limit Bonesupport’s market access.
• Spine Market Entry Risk: The planned entry into the U.S. spinal fusion market represents a significant opportunity but also a substantial risk. This segment is the most competitive area of the orthobiologics market, with deeply entrenched competitors and strong surgeon loyalties.⁸² Bonesupport will be launching its non-antibiotic BVF product into this market, where its value proposition is less differentiated than in infection management. Failure to gain meaningful traction in the spine market would limit a key pillar of the company’s long-term growth strategy.

Execution and Operational Risks

• U.S. Commercial Scaling: The company’s growth is heavily dependent on its ability to continue to effectively manage and scale its U.S. network of independent distributors. Any disruption to this network, loss of key distributors, or failure to adequately support them could impede sales momentum.¹⁷
• Leadership Transition: The change in CEO scheduled for September 2025 occurs at a critical juncture in the company’s growth story.⁷⁹ A successful and seamless leadership transition is crucial to maintaining strategic focus and operational execution. Any missteps or significant changes in strategy under the new leadership could introduce uncertainty and risk.
• Supply Chain and Manufacturing: Bonesupport relies on third-party contract manufacturers for the production of its products.⁹⁷ The company is therefore exposed to potential supply chain disruptions, manufacturing quality issues, or capacity constraints at its suppliers, any of which could impact its ability to meet the rapidly growing demand for its products.

X. Valuation Analysis Framework

This analysis does not provide a specific valuation or price target for Bonesupport Holding AB. Instead, it offers a framework of methodologies and key considerations that an investor could use to assess the company’s valuation.

Peer Group Comparison

A relative valuation approach would involve comparing Bonesupport’s trading multiples to those of a carefully selected peer group. Given its profile as a high-growth, newly profitable, small-cap medical device company, an appropriate peer group would include:

• High-Growth Small/Mid-Cap Orthopedic and Spine Companies: Such as Orthofix Medical Inc., Bioventus LLC, and other specialized players.
• General High-Growth Medical Technology Companies: Companies in other medical fields with similar financial characteristics (e.g., >40% revenue growth, high gross margins, recent inflection to profitability).

Key metrics for comparison would include Enterprise Value to Sales (EV/Sales) and, now that the company is profitable, Price to Earnings (P/E) on a forward-looking basis. It is anticipated that Bonesupport would trade at a significant premium to more mature, slower-growing orthopedic companies due to its superior growth profile. The central question for a relative valuation is whether its current premium fully and fairly reflects its future growth prospects relative to its peers.

Historical Valuation Ranges

An analysis of Bonesupport’s own historical valuation can provide context. The company’s stock price and, consequently, its valuation multiples have expanded significantly since 2022. The share price ranged from SEK 74.55 to SEK 190.70 in 2023 and from SEK 172.20 to SEK 397.40 in 2024.³ This re-rating has been driven by the successful de-risking of its U.S. strategy through key regulatory and reimbursement milestones and the clear demonstration of its path to profitability. Tracking the evolution of its EV/Sales multiple in relation to its revenue growth rate and the achievement of these milestones would provide insight into how the market has priced in its success over time.

Discounted Cash Flow (DCF) Analysis

A DCF analysis would be a primary method for assessing intrinsic value, but its output would be highly sensitive to several key assumptions:

• U.S. Market Penetration Rate: The single most important assumption would be the peak market share that CERAMENT G can achieve in the U.S. extremities market (bone infection and trauma) and the market share that CERAMENT BVF can achieve in the U.S. spine market.
• Timeline and Probability of Success for CERAMENT V: The model would need to incorporate assumptions about the timing of the U.S. launch of CERAMENT V and its potential contribution to revenue and market share.
• Long-Term Operating Margins: The forecast would need to make an assumption about the company’s terminal operating margin, reflecting the scalability of the business model.
• Discount Rate: The weighted average cost of capital (WACC) used to discount future cash flows would need to appropriately reflect the risk profile of a high-growth medical device company with significant product and market concentration.

Qualitative Assessment

Finally, any quantitative valuation must be tempered by a qualitative assessment of the company’s strategic position. Factors that would support a premium valuation include:

• First-Mover Advantage: The company’s position as the first and only approved provider of a resorbable, antibiotic-eluting bone graft in the U.S.
• High Barriers to Entry: The regulatory moat created by the De Novo classification and the extensive clinical data package.
• Large Addressable Markets: The significant untapped market opportunities in U.S. trauma and, particularly, spinal fusion.
• Strong Health Economic Value Proposition: The clear cost-saving benefits of a single-stage procedure, which aligns with the priorities of healthcare systems.

Conversely, factors that might temper the valuation include the high degree of competition in the broader orthobiologics space, the execution risk associated with the spine launch, and the concentration risk of relying on a single technology platform. A comprehensive valuation would need to weigh these qualitative factors alongside the quantitative outputs of the other methodologies.

Works cited

1. BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient’s own bone and have the capability of eluting drugs. BONESUPPORT’s bone graft substitutes are based on the patented technology platform CERAMENT. The company is conducting several clinical studies to further demonstrate the clinical and health economic benefits its products deliver. The company is based in Lund, Sweden, and the net sales amounted to SEK 899 million in 2024. Please visit www.bonesupport.com for more information. – Investor – BONESUPPORT, accessed August 29, 2025, https://investor.bonesupport.com/en/
2. Bonesupport Holding | Investor Relations / Filings / Financial statement, accessed August 29, 2025, https://financialreports.eu/companies/bonesupport-holding/
3. ANNUAL REPORT – MFN.se, accessed August 29, 2025, https://storage.mfn.se/f0cd0105-b6f3-4198-acb2-500224405231/bonesupport-2024-en.pdf
4. Contact Us – BONESUPPORT, accessed August 29, 2025, https://www.bonesupport.com/sv/contact-us/
5. Home – BONESUPPORT, accessed August 29, 2025, https://www.bonesupport.com/en-us/
6. Medical Professionals – BONESUPPORT, accessed August 29, 2025, https://www.bonesupport.com/en-eu/medical-professionals/
7. CERAMENT® BONE VOID FILLER – BONESUPPORT, accessed August 29, 2025, https://www.bonesupport.com/en-us/products/cerament-bone-void-filler/
8. The CERAMENT® product portfolio – BONESUPPORT, accessed August 29, 2025, https://www.bonesupport.com/en-us/products/
9. white wound drainage – bonesupport, accessed August 29, 2025, https://www.bonesupport.com/wp-content/uploads/2022/09/PR-01259-01-CERAMENT-White-wound-drainage-advice-sheet-final.pdf
10. BONE VOID FILLER – bonesupport, accessed August 29, 2025, https://www.bonesupport.com/wp-content/uploads/2025/06/PR-01122-02-en-US-06-2025-CERAMENT-BVF-Key-Clinical-Evidence.pdf
11. CERAMENT® G with Gentamicin – bonesupport, accessed August 29, 2025, https://www.bonesupport.com/wp-content/uploads/2024/09/PR-01271-02-en-US-09-2024-CERAMENT-G-VAC-Guide-USA.pdf
12. Injectable Antibiotic-Eluting Bone Graft – bonesupport, accessed August 29, 2025, https://www.bonesupport.com/wp-content/uploads/2022/06/PR-01271-01-en-US-05-2022-CERAMENT-G-VAC-Guide-final.pdf
13. CERAMENT® G – BONESUPPORT, accessed August 29, 2025, https://www.bonesupport.com/en-eu/products/cerament-g/
14. Current technology – BONESUPPORT, accessed August 29, 2025, https://www.bonesupport.com/en-eu/innovation/current-technology/
15. CURRENT TECHNOLOGY – BONESUPPORT, accessed August 29, 2025, https://www.bonesupport.com/en-us/innovation/pipeline-copy/
16. ANNUAL REPORT – MFN.se, accessed August 29, 2025, https://storage.mfn.se/17cdae01-59e8-41de-9aac-525afe0410cf/bonesupport-2023-en.pdf
17. SUCCESFULLY ESTABLISHED NEW US DISTRIBUTION STRUCTURE – bonesupport, accessed August 29, 2025, https://bonesupport.com/wp-content/uploads/2020/08/bonesupport-jan-sep-2018-interim-report-final-en.pdf
18. BONESUPPORT starts selling CERAMENT® BONE VOID FILLER Direct in the US via its own New Distributor Network, accessed August 29, 2025, https://www.bonesupport.com/en-us/media/press-release/bonesupport-starts-selling-cerament-bone-void-filler-direct-in-the-us-via-its-own-new-distributor-network/
19. ANNUAL REPORT – bonesupport, accessed August 29, 2025, https://bonesupport.com/wp-content/uploads/2020/08/Annual-Report_2020_EN_final.pdf
20. BONESUPPORT™ Reports Expansion of Company’s CERAMENT® Drug Eluting Procedure Registry, accessed August 29, 2025, https://www.bonesupport.com/en-us/media/press-release/bonesupport-reports-expansion-of-companys-cerament-drug-eluting-procedure-registry/
21. BONESUPPORT HOLDING AB (publ) – Information on the impact of tariffs in connection with the company’s import into the United States, accessed August 29, 2025, https://www.bonesupport.com/en-us/media/press-releases/bonesupport-holding-ab-publ-information-on-the-impact-of-tariffs-in-connection-with-the-companys-import-into-the-united-states/
22. BONESUPPORT receives market authorization for CERAMENT G in …, accessed August 29, 2025, https://www.bonesupport.com/en-eu/media/press-releases/bonesupport-receives-market-authorization-for-cerament-g-in-the-us/
23. May 17, 2022 BONESUPPORT AB Hollace Saas Rhodes Vice President, Orthopedic Regulatory Affairs MCRA, LLC 803 7th Street NW, F – accessdata.fda.gov, accessed August 29, 2025, https://www.accessdata.fda.gov/cdrh_docs/pdf21/DEN210044.pdf
24. CERAMENT® G RECEIVES FDA CLEARANCE FOR OPEN FRACTURES – bonesupport, accessed August 29, 2025, https://www.bonesupport.com/en-us/media/press-releases/cerament-r-g-receives-fda-clearance-for-open-fractures/
25. THE GROWTH JOURNEY CONTINUES – MFN.se, accessed August 29, 2025, https://storage.mfn.se/d7637984-3bfb-4db7-a561-a65e6db00a60/bonesupport-q1-2024-en.pdf
26. The market submission for CERAMENT® V in the US will be a 510(k) – BONESUPPORT, accessed August 29, 2025, https://www.bonesupport.com/en-us/media/press-releases/the-market-submission-for-cerament-r-v-in-the-us-will-be-a-510-k/
27. BONESUPPORT HOLDING AB (publ) – Publishes year end report 2023, accessed August 29, 2025, https://www.bonesupport.com/en-us/media/press-releases/bonesupport-holding-ab-publ-publishes-year-end-report-2023/
28. Emil’s Intro Presentation – Investor – BONESUPPORT, accessed August 29, 2025, https://investor.bonesupport.com/wp-content/uploads/2024/05/Bonesupport-CMD2022-presentations.pdf
29. Orthobiologics Market Size, Share | In-depth Analysis [2032] – Fortune Business Insights, accessed August 29, 2025, https://www.fortunebusinessinsights.com/industry-reports/orthobiologics-market-100173
30. Orthobiologics Market Size And Share | Industry Report, 2033 – Grand View Research, accessed August 29, 2025, https://www.grandviewresearch.com/industry-analysis/orthobiological-products-market
31. Orthobiologics Market Size, Share| Growth| Forecast, 2032 – Global Market Insights, accessed August 29, 2025, https://www.gminsights.com/industry-analysis/orthobiologics-market
32. Orthobiologics Market Size, Share & Outlook to 2033, accessed August 29, 2025, https://www.marketgrowthreports.com/market-reports/orthobiologics-market-115238
33. Orthobiologics Market Size and YoY Growth Rate, 2025-2032 – Coherent Market Insights, accessed August 29, 2025, https://www.coherentmarketinsights.com/market-insight/orthobiologics-market-1306
34. Orthobiologics Market Size to Surge USD 11.95 Billion by 2034 – Precedence Research, accessed August 29, 2025, https://www.precedenceresearch.com/orthobiologics-market
35. Global Orthobiologics Market By Type (Viscosupplementation, Synthetic Biologics, Bone Growth Factors, Demineralized Bone Matrix, and Others), By Applications (Spinal Fusion, Maxillofacial and Dental, Soft Tissue Repair, and Fracture Surgery), By End User, By Region and Companies – Market.us, accessed August 29, 2025, https://market.us/report/orthobiologics-market/
36. Bone Graft Substitutes Market Size, Share & Analysis [2032] – Fortune Business Insights, accessed August 29, 2025, https://www.fortunebusinessinsights.com/bone-graft-substitutes-market-103106
37. Bone Grafts and Substitutes Market Size and Forecast 2025 to 2034 – Precedence Research, accessed August 29, 2025, https://www.precedenceresearch.com/bone-grafts-and-substitutes-market
38. Bone Grafts and Substitutes Market Size, Share | Trends 2033, accessed August 29, 2025, https://www.alliedmarketresearch.com/bone-graft-substitutes-market
39. Bone Grafts And Substitutes Market Size, Share Report 2030 – Grand View Research, accessed August 29, 2025, https://www.grandviewresearch.com/industry-analysis/bone-grafts-substitutes-market
40. Orthobiologics Market to Reach USD 12.2 Billion by 2035, Driven by Rising Demand for Regenerative Therapies – NORTHEAST – NEWS CHANNEL NEBRASKA, accessed August 29, 2025, https://northeast.newschannelnebraska.com/story/53023772/orthobiologics-market-to-reach-usd-122-billion-by-2035-driven-by-rising-demand-for-regenerative-therapies
41. Orthobiologics Market Size, Growth Analysis, Report 2034, accessed August 29, 2025, https://www.marketresearchfuture.com/reports/orthobiologics-market-7826
42. Bone Grafts and Substitutes Market Size, Trends and Competitive Landscape, accessed August 29, 2025, https://www.towardshealthcare.com/insights/bone-grafts-and-substitutes-market-sizing
43. U.S. Bone Grafts & Substitutes Market | Industry Report 2030 – Grand View Research, accessed August 29, 2025, https://www.grandviewresearch.com/industry-analysis/us-bone-grafts-substitutes-market-report
44. ALLOGRAFT TISSUE BONE GRAFTING (Spine and Orthopaedic) – Medtronic, accessed August 29, 2025, https://www.medtronic.com/en-us/l/patients/treatments-therapies/bone-grafting-spine-orthopaedic/bone-graft-options/allograft-tissue.html
45. Analyzing the Orthopedic Trauma Care Industry in the Americas – World Health Expo, accessed August 29, 2025, https://www.worldhealthexpo.com/content/dam/esa/emea/worldhealthexpo/events/healthcare/miami/en/2025/pdfs/FIME25-orthopedics-industry-report.pdf
46. North America Orthobiologics Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032, accessed August 29, 2025, https://www.databridgemarketresearch.com/reports/north-america-orthobiologics-market
47. Orthobiologics Market: Key Players, Industry Analysis & Future Opportunities – Medium, accessed August 29, 2025, https://medium.com/@CIhealthinsightshub/orthobiologics-market-key-players-industry-analysis-future-opportunities-38184ce01d14
48. Orthobiologics Market Size, Growth & Industry Analysis | 2030 – Mordor Intelligence, accessed August 29, 2025, https://www.mordorintelligence.com/industry-reports/orthobiologics-market
49. Competitive Landscape Scenario: Orthopedic Devices Industry (Joint Replacement, Trauma & Extremities, Sports Medicine, and Orthobiologics) – Grand View Research, accessed August 29, 2025, https://www.grandviewresearch.com/market-trends/orthopedic-devices-company-market-share-analysis
50. Bone Grafting – Spine and Orthopaedic – Important Safety Information | Medtronic, accessed August 29, 2025, https://www.medtronic.com/en-us/l/patients/treatments-therapies/bone-grafting-spine-orthopaedic/important-safety-information.html
51. Vitoss | Stryker, accessed August 29, 2025, https://www.stryker.com/us/en/trauma-and-extremities/products/vitoss.html
52. Triosite® Bioactive Ceramic Bone Graft Substitute – Hospitrauma, accessed August 29, 2025, http://www.hospitrauma.com/download/HOSPITRAUMA_ZimmerBiomet_Triosite.pdf
53. genex® Bone Graft Substitute – Zimmer Biomet, accessed August 29, 2025, https://www.zimmerbiomet.com/en/products-and-solutions/specialties/foot-and-ankle/genex-bone-graft-substitute.html
54. Capitalizing on the Growth Potential of Orthobiologics – bonezone, accessed August 29, 2025, https://bonezonepub.com/2022/11/01/capitalizing-on-the-growth-potential-of-orthobiologics/
55. BONESUPPORT HOLDING AB (publ) – publishes Q2 2025 Interim report, accessed August 29, 2025, https://www.bonesupport.com/en-eu/media/press-releases/bonesupport-holding-ab-publ-publishes-q2-2025-interim-report/
56. CMS APPROVES NTAP FOR CERAMENT® G IN OPEN FRACTURES, PROVIDING ADDITIONAL HOSPITAL REIMBURSEMENT STARTING OCTOBER 1, 2025 – BONESUPPORT, accessed August 29, 2025, https://www.bonesupport.com/en-us/media/press-releases/cms-approves-ntap-for-cerament-r-g-in-open-fractures-providing-additional-hospital-reimbursement-starting-october-1-2025
57. Ceramic Biocomposites as Biodegradable Antibiotic Carriers in the Treatment of Bone Infections – bonesupport, accessed August 29, 2025, https://bonesupport.com/wp-content/uploads/2020/09/ferguson-ceramic-biocomposites-as-biodegradable-antibiotic-carriers-in-the-treatment-of-bone-infections.pdf
58. Cost-effectiveness of CERAMENT® G in the United States presented at ISPOR conference, accessed August 29, 2025, https://www.bonesupport.com/en-eu/media/press-releases/cost-effectiveness-of-cerament-r-g-in-the-united-states-presented-at-ispor-conference/
59. Proven bone remodeling with local antibiotic elution – bonesupport, accessed August 29, 2025, https://www.bonesupport.com/wp-content/uploads/2024/05/Value-Guide-CG-CV-English.pdf
60. 70,000 OVER 240+ – bonesupport, accessed August 29, 2025, https://www.bonesupport.com/wp-content/uploads/2022/06/Key-Clinical-Evidence-PR-01224-03-en-AU-CA-US-12-2022.pdf
61. CERTiFy Clinical Trial – BONESUPPORT, accessed August 29, 2025, https://www.bonesupport.com/en-us/innovation/certify/
62. Medtronic’s INFUSE Bone Graft trial meets predefined early success criteria, accessed August 29, 2025, https://www.medicaldevice-network.com/news/medtronic-infuse-bone-graft-trial/
63. Augment | Stryker, accessed August 29, 2025, https://www.stryker.com/us/en/foot-and-ankle/products/augment.html
64. Final price in BONESUPPORT™’s initial public offering set at SEK 29 per share – trading on Nasdaq Stockholm commences today, accessed August 29, 2025, https://www.bonesupport.com/en-eu/media/press-release/final-price-in-bonesupports-initial-public-offering-set-at-sek-29-per-share-trading-on-nasdaq-stockholm-commences-today/
65. BONESUPPORT™ – Pipeline Project Targeting Bioceramics Capable of Enhancing Bone Growth Awarded SEK 8 million Grant from Vinnova Sweden, accessed August 29, 2025, https://www.bonesupport.com/en-eu/media/press-release/bonesupport-pipeline-project-targeting-bioceramics-capable-of-enhancing-bone-growth-awarded-sek-8-million-grant-from-vinnova-sweden/
66. BONESUPPORT: Products for the medical device industry require a focused patent strategy, accessed August 29, 2025, https://www.gipc.dk/en/case-bonesupport/
67. Patents Assigned to Bone Support AB, accessed August 29, 2025, https://patents.justia.com/assignee/bone-support-ab
68. BONESUPPORT signs distribution agreement with OrthoPediatrics, accessed August 29, 2025, https://www.bonesupport.com/en-eu/media/press-release/bonesupport-signs-distribution-agreement-with-orthopediatrics/
69. BONESUPPORT – ABG Private Banking, accessed August 29, 2025, https://abgprivatebanking.se/wp-content/uploads/2025/03/bone.pdf
70. ANNUAL REPORT – bonesupport, accessed August 29, 2025, https://bonesupport.com/wp-content/uploads/2020/10/bonesupport-annual-report-2018-en.pdf
71. BONESUPPORT HOLDING AB (publ) – publishes year end report 2024, accessed August 29, 2025, https://www.bonesupport.com/en-us/media/press-releases/bonesupport-holding-ab-publ-publishes-year-end-report-2024/
72. Bonesupport Q2 2025 slides: 40% CER growth as CERAMENT G drives US momentum, accessed August 29, 2025, https://www.investing.com/news/company-news/bonesupport-q2-2025-slides-40-cer-growth-as-cerament-g-drives-us-momentum-93CH-4134805
73. BONESUPPORT Investor presentation, accessed August 29, 2025, https://www.bonesupport.com/wp-content/uploads/2020/08/skeleton-follow-up-presentation-press-meeting.pdf
74. Press Releases – BONESUPPORT, accessed August 29, 2025, https://www.bonesupport.com/en-us/media/press-releases/
75. BONESUPPORT HOLDING AB (publ) – publishes Q1 2025 Interim report, accessed August 29, 2025, https://www.bonesupport.com/en-eu/media/press-releases/bonesupport-holding-ab-publ-publishes-q1-2025-interim-report/
76. BONESUPPORT HOLDING AB (publ) – publishes Q3 2024 Interim report, accessed August 29, 2025, https://www.bonesupport.com/en-us/media/press-releases/bonesupport-holding-ab-publ-publishes-q3-2024-interim-report/
77. CHANGE IN THE MANAGEMENT TEAM – BONESUPPORT, accessed August 29, 2025, https://www.bonesupport.com/en-us/media/press-releases/change-in-the-management-team/
78. CHANGE IN THE MANAGEMENT TEAM – Investor – BONESUPPORT, accessed August 29, 2025, https://investor.bonesupport.com/en/investors/press-releases/change-in-the-management-team
79. Upcoming CEO change. Emil Billbäck will transfer to a role as Senior Advisor. Torbjörn Sköld will start as CEO effective September 1st, 2025 – BONESUPPORT, accessed August 29, 2025, https://www.bonesupport.com/en-us/media/press-releases/upcoming-ceo-change-emil-billback-will-transfer-to-a-role-as-senior-advisor-torbjorn-skold-will-start-as-ceo-effective-september-1st-2025/
80. BONESUPPORT’s incoming CEO acquires shares, accessed August 29, 2025, https://www.bonesupport.com/en-us/media/press-releases/bonesupports-incoming-ceo-acquires-shares/
81. Capital Markets Day 2023 – Investor – BONESUPPORT, accessed August 29, 2025, https://investor.bonesupport.com/wp-content/uploads/2024/05/BONESUPPORT-CMD-2023.pdf
82. bonesupport-presentation-q2-2025.pdf – MFN.se, accessed August 29, 2025, https://storage.mfn.se/a/bonesupport-holding/3cca1d3c-6691-420b-9995-1dac38526ba5/bonesupport-presentation-q2-2025.pdf
83. Frost & Sullivan Acclaims BONESUPPORT’s Growth Potential Bolstered by its Unique Platform Technology, CERAMENT, accessed August 29, 2025, https://www.frost.com/news/press-releases/frost-sullivan-acclaims-bonesupports-growth-potential-bolstered-its-unique-platform-technology-cerament/
84. Earnings call transcript: Bonesupport Holding AB reports strong Q2 2025 growth, accessed August 29, 2025, https://www.investing.com/news/transcripts/earnings-call-transcript-bonesupport-holding-ab-reports-strong-q2-2025-growth-93CH-4134896
85. Pipeline – BONESUPPORT, accessed August 29, 2025, https://www.bonesupport.com/en-eu/innovation/pipeline/
86. PRESS RELEASE – BONESUPPORT highlights significant strategic progress at Capital Market Days in Stockholm and London, accessed August 29, 2025, https://www.bonesupport.com/wp-content/uploads/2020/09/pr0770-01-en-eu.pdf
87. BONESUPPORT Signs Agreement with MTF Biologics to Expand US Product Offering, accessed August 29, 2025, https://www.bonesupport.com/en-us/media/press-release/bonesupport-signs-agreement-with-mtf-biologics-to-expand-us-product-offering/
88. The Board of Directors of BONESUPPORT has resolved on transfer of own shares and issue of series C shares, accessed August 29, 2025, https://www.bonesupport.com/en-us/media/press-releases/the-board-of-directors-of-bonesupport-has-resolved-on-transfer-of-own-shares-and-issue-of-series-c-shares/
89. BONESUPPORT hosts Capital Markets Day 2023, accessed August 29, 2025, https://www.bonesupport.com/en-eu/media/press-releases/bonesupport-hosts-capital-markets-day-2023/
90. BONESUPPORT HOLDING AB (publ) – publishes Q2 2024 Interim report, accessed August 29, 2025, https://www.bonesupport.com/en-us/media/press-releases/bonesupport-holding-ab-publ-publishes-q2-2024-interim-report/
91. Announced Insider Trading – Investor – BONESUPPORT, accessed August 29, 2025, https://investor.bonesupport.com/en/investors/press-releases/announced-insider-trading-1
92. ANNOUNCED INSIDER TRADING – BONESUPPORT, accessed August 29, 2025, https://www.bonesupport.com/en-us/media/press-releases/announced-insider-trading-3
93. Announced Insider Trading – BONESUPPORT, accessed August 29, 2025, https://www.bonesupport.com/en-us/media/press-releases/announced-insider-trading-2/
94. MAUDE Adverse Event Report: BONESUPPORT AB CERAMENT BONE VOID FILLER, accessed August 29, 2025, https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfmaude/detail.cfm?mdrfoi__id=20964804&pc=MQV
95. Orthobiologics Market to Reach USD 11.7 Bn by 2033 | CAGR 5.7%, accessed August 29, 2025, https://dimensionmarketresearch.com/report/orthobiologics-market/
96. BONESUPPORT creates its own US Commercial Platform, accessed August 29, 2025, https://www.bonesupport.com/en-us/media/press-release/bonesupport-creates-its-own-us-commercial-platform/
97. Sustainability – bonesupport, accessed August 29, 2025, https://www.bonesupport.com/en-eu/bonesupport/sustainability/